Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders' ability to sell cheaper versions of the drugs.
The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
The lawsuit claims the FDA's finding that there was no longer a shortage of the drugs' active ingredient semaglutide was ...
The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...
Then, the Ozempic boom happened. Celebrities like Khloé Kardashian and Oprah Winfrey were sharing their experience with ...
Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...
Newser on MSN8h
FDA Change on Ozempic to Shake Up the MarketThe shortage of Ozempic and Wegovy has been declared over by the Food and Drug Administration, a change that suggests higher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback